Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | FPR2 | P25090 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GRK2 | P25098 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889076 | 0.97 | HTT (0.54) | SMN1; SMN2HTTKDM4ERAB9ANPC1 | |
| SCHEMBL889032 | 0.90 | KMT2A (0.54) | SMN1; SMN2KDM4ERAB9ANPC1KMT2A | |
| SCHEMBL889041 | 0.83 | KMT2A (0.66) | SMN1; SMN2KDM4ERAB9ANPC1KMT2A | |
| SCHEMBL7824367 | 0.79 | RAB9A (0.72) | SMN1; SMN2HTTKDM4ERAB9AKMT2A | |
| SCHEMBL12810219 | 0.76 | FPR2 (0.47) | RAB9ANPC1KMT2AFPR2MEN1 | |
| SCHEMBL12203732 | 0.76 | HPGD (0.44) | KDM4EKMT2AMEN1MAPTHPGD | |
| SCHEMBL14224001 | 0.75 | HTT (0.47) | SMN1; SMN2HTTKDM4ERAB9ANPC1 | |
| SCHEMBL791775 | 0.75 | HTT (0.50) | SMN1; SMN2HTTKDM4ERAB9ANPC1 | |
| SCHEMBL2719839 | 0.74 | NAMPT (0.67) | SMN1; SMN2HTTKDM4ERAB9ANPC1 | |
| SCHEMBL12810218 | 0.74 | FPR2 (0.47) | SMN1; SMN2HTTKDM4ERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8703938-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | SMN1; SMN2 4269/4885HTT 4573/4885KDM4E 1139/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | SMN1; SMN2 4269/4885HTT 4573/4885KDM4E 1139/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | SMN1; SMN2 4269/4885HTT 4573/4885KDM4E 1139/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | SMN1; SMN2 4269/4885HTT 4573/4885KDM4E 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.